Literature DB >> 11514501

Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion.

M Beghetti1, M Berner, P C Rimensberger.   

Abstract

Primary pulmonary hypertension is a rare disease in childhood associated with a poor prognosis. However, during the past 10 years, pulmonary vasodilator treatment has somewhat improved its prognosis. Long term continuous infusion of prostacyclin (epoprostenol) has been shown to improve physical capacity and to reduce mortality in primary and secondary pulmonary hypertension. It has been reported in adults that daily repetitive inhalation of iloprost, a prostacyclin analogue, seems also suitable for long term therapy of pulmonary hypertension. Repetitive inhalation of iloprost was administered to a 5 year old boy with severe primary pulmonary hypertension. He showed continuous clinical improvement without any side effects over the three years of treatment. This treatment may offer an alternative to continuous intravenous prostacyclin infusion and obviates the need for a permanent central venous catheter.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514501      PMCID: PMC1729896          DOI: 10.1136/heart.86.3.e10

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms.

Authors:  P C Rimensberger; I Spahr-Schopfer; M Berner; E Jaeggi; A Kalangos; B Friedli; M Beghetti
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

2.  Role of atrial septostomy in the treatment of pulmonary vascular disease.

Authors:  R J Barst
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

3.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

Authors:  V V McLaughlin; D E Genthner; M M Panella; S Rich
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

4.  Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.

Authors:  M M Hoeper; M Schwarze; S Ehlerding; A Adler-Schuermeyer; E Spiekerkoetter; J Niedermeyer; M Hamm; H Fabel
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

5.  Vasodilator therapy for primary pulmonary hypertension in children.

Authors:  R J Barst; G Maislin; A P Fishman
Journal:  Circulation       Date:  1999-03-09       Impact factor: 29.690

Review 6.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

7.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Authors:  R J Barst; L J Rubin; W A Long; M D McGoon; S Rich; D B Badesch; B M Groves; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; L M Clayton; M M Jöbsis; S D Blackburn; D Shortino; J W Crow
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

8.  Factors that influence the outcome of primary pulmonary hypertension.

Authors:  A Rozkovec; P Montanes; C M Oakley
Journal:  Br Heart J       Date:  1986-05

9.  Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.

Authors:  T Higenbottam; A Y Butt; A McMahon; R Westerbeck; L Sharples
Journal:  Heart       Date:  1998-08       Impact factor: 5.994

10.  Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.

Authors:  H Olschewski; D Walmrath; R Schermuly; A Ghofrani; F Grimminger; W Seeger
Journal:  Ann Intern Med       Date:  1996-05-01       Impact factor: 25.391

  10 in total
  7 in total

Review 1.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

2.  Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost.

Authors:  M Emmel; B Keuth; S Schickendantz
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

Review 3.  Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.

Authors:  John S Kim; Julia McSweeney; Joanne Lee; Dunbar Ivy
Journal:  Pediatr Crit Care Med       Date:  2016-03       Impact factor: 3.624

4.  Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.

Authors:  D Dunbar Ivy; Aimee K Doran; Kelly J Smith; George B Mallory; Maurice Beghetti; Robyn J Barst; Daniela Brady; Yuk Law; Donna Parker; Lori Claussen; Steven H Abman
Journal:  J Am Coll Cardiol       Date:  2008-01-15       Impact factor: 24.094

Review 5.  Drug Treatment of Pulmonary Hypertension in Children.

Authors:  Catherine M Avitabile; Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 6.  Current challenges in pediatric pulmonary hypertension.

Authors:  Shinichi Takatsuki; David Dunbar Ivy
Journal:  Semin Respir Crit Care Med       Date:  2013-09-13       Impact factor: 3.119

Review 7.  Review of inhaled iloprost for the control of pulmonary artery hypertension in children.

Authors:  Cecile Tissot; Maurice Beghetti
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.